Rivaroxaban, Warfarin Show Similar Safety, Efficacy for Patients with AFib and Bioprosthetic Mitral Valve
In the largest study to assess the safety and efficacy of direct oral anticoagulants in patients with atrial fibrillation and a bioprosthetic mitral valve, rivaroxaban demonstrated noninferiority to warfarin in the mean length of event-free survival time, according to late-breaking trial results presented Saturday at the American Heart Association Scientific Sessions 2020 virtual conference.